Monetary Management Group Inc. lessened its stake in shares of Zoetis Inc (NYSE:ZTS) by 44.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,265 shares of the company’s stock after selling 1,025 shares during the quarter. Monetary Management Group Inc.’s holdings in Zoetis were worth $149,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. TI Trust Inc. purchased a new stake in shares of Zoetis during the 4th quarter valued at about $26,000. ICW Investment Advisors LLC purchased a new stake in shares of Zoetis during the 4th quarter valued at about $27,000. Lion Street Advisors LLC purchased a new stake in shares of Zoetis during the 1st quarter valued at about $30,000. Sowa Financial Group Inc. purchased a new stake in shares of Zoetis during the 4th quarter valued at about $31,000. Finally, Danda Trouve Investment Management Inc. purchased a new stake in shares of Zoetis during the 4th quarter valued at about $32,000. 91.45% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have recently weighed in on ZTS shares. SunTrust Banks reiterated a “hold” rating and issued a $145.00 price objective on shares of Zoetis in a research note on Friday, February 14th. Jefferies Financial Group started coverage on shares of Zoetis in a research note on Wednesday, May 27th. They issued a “buy” rating and a $152.00 price objective on the stock. Bank of America reiterated a “hold” rating and issued a $145.00 price objective on shares of Zoetis in a research note on Wednesday, February 12th. Credit Suisse Group reiterated a “buy” rating and issued a $147.00 price objective on shares of Zoetis in a research note on Monday, May 18th. Finally, Argus reiterated a “buy” rating on shares of Zoetis in a research note on Wednesday, June 3rd. Seven analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $141.53.
NYSE ZTS traded down $8.38 on Thursday, reaching $131.53. 57,926 shares of the stock were exchanged, compared to its average volume of 2,554,551. Zoetis Inc has a one year low of $90.14 and a one year high of $146.26. The firm has a market capitalization of $64.64 billion, a PE ratio of 39.56, a PEG ratio of 5.02 and a beta of 0.79. The company’s 50-day simple moving average is $130.82 and its two-hundred day simple moving average is $129.69. The company has a current ratio of 2.77, a quick ratio of 1.91 and a debt-to-equity ratio of 2.22.
Zoetis (NYSE:ZTS) last released its earnings results on Wednesday, May 6th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.86 by $0.09. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Zoetis had a net margin of 25.41% and a return on equity of 67.72%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.88 EPS. Sell-side analysts forecast that Zoetis Inc will post 3.33 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 17th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.61%. The ex-dividend date of this dividend is Thursday, July 16th. Zoetis’s payout ratio is currently 21.98%.
In other news, EVP Heidi C. Chen sold 1,179 shares of Zoetis stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $127.44, for a total transaction of $150,251.76. Following the sale, the executive vice president now owns 17,514 shares in the company, valued at $2,231,984.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kristin C. Peck sold 10,500 shares of Zoetis stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $131.31, for a total transaction of $1,378,755.00. Following the sale, the chief executive officer now owns 43,759 shares in the company, valued at approximately $5,745,994.29. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,820 shares of company stock worth $2,992,087. Company insiders own 0.17% of the company’s stock.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: Learning About the VIX – Volatility Index
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.